Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Poluzzi

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
International Journal of Environmental Research and Public Health|June 24, 2022
Time-Trends of Drug-Drug Interactions among Elderly Outpatients in the Piedmont Region (Italy): A Population-Based StudyElisabetta Galai, Lorenza Scotti, Marco Gilardetti, et al.
British Journal of Clinical Pharmacology|March 18, 2025
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines AgencyValentina Giunchi, Michele Fusaroli, Agnese Cangini, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|July 31, 2023
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting SystemMichele Fusaroli, Arndis Simonsen, Stephanie A Borrie, et al.
The International Journal of Pharmacy Practice|December 31, 2024
Environmental sustainability-an essential component of rational use of medicinesValentina Giunchi, Michele Fusaroli, Elkanah Linder, et al.
British Journal of Clinical Pharmacology|June 27, 2006
An update on the first decade of the European centralized procedure: how many innovative drugs?Domenico Motola, Fabrizio De Ponti, Elisabetta Poluzzi, et al.
British Journal of Clinical Pharmacology|April 29, 2023
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water suppliesValentina Giunchi, Michele Fusaroli, Elkanah Linder, et al.
Drug Safety|June 10, 2017
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence MappingIppazio Cosimo Antonazzo, Emanuel Raschi, Luca Vignatelli, et al.
Acta Diabetologica|June 17, 2019
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting systemIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Infection|September 18, 2015
Response to comment on: "antibiotic use varies substantially among adults--a cross‑national study from five European Countries in the ARITMO project"Anil Mor, Reimar Wernich Thomsen, Trine Frøslev, et al.
Drug Safety|April 5, 2013
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System databaseElisabetta Poluzzi, Emanuel Raschi, Ariola Koci, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
International Journal of Environmental Research and Public Health|June 24, 2022
Time-Trends of Drug-Drug Interactions among Elderly Outpatients in the Piedmont Region (Italy): A Population-Based StudyElisabetta Galai, Lorenza Scotti, Marco Gilardetti, et al.
British Journal of Clinical Pharmacology|March 18, 2025
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines AgencyValentina Giunchi, Michele Fusaroli, Agnese Cangini, et al.
Journal of Speech, Language, and Hearing Research : JSLHR|July 31, 2023
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting SystemMichele Fusaroli, Arndis Simonsen, Stephanie A Borrie, et al.
The International Journal of Pharmacy Practice|December 31, 2024
Environmental sustainability-an essential component of rational use of medicinesValentina Giunchi, Michele Fusaroli, Elkanah Linder, et al.
British Journal of Clinical Pharmacology|June 27, 2006
An update on the first decade of the European centralized procedure: how many innovative drugs?Domenico Motola, Fabrizio De Ponti, Elisabetta Poluzzi, et al.
British Journal of Clinical Pharmacology|April 29, 2023
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water suppliesValentina Giunchi, Michele Fusaroli, Elkanah Linder, et al.
Drug Safety|June 10, 2017
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence MappingIppazio Cosimo Antonazzo, Emanuel Raschi, Luca Vignatelli, et al.
Acta Diabetologica|June 17, 2019
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting systemIppazio Cosimo Antonazzo, Elisabetta Poluzzi, Emanuele Forcesi, et al.
Infection|September 18, 2015
Response to comment on: "antibiotic use varies substantially among adults--a cross‑national study from five European Countries in the ARITMO project"Anil Mor, Reimar Wernich Thomsen, Trine Frøslev, et al.
Drug Safety|April 5, 2013
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System databaseElisabetta Poluzzi, Emanuel Raschi, Ariola Koci, et al.
Pageof 19